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1 |  INTRODUCTION
Severe and treatment‐resistant headache sometimes occurs in 
patients with systemic lupus erythematosus, so called lupus‐
headache.It is defined as a persistent headache that “may be 
migrainous, but must be nonresponsive to narcotic analge-
sia”.1 We report a case of similar severe and disabling head-
ache in a patient with primary Sjögren's syndrome (pSS) that 
was successfully treated with intrathecal rituximab.
2 |  CASE HISTORY
A 41‐year‐old woman with a nine‐year history of pSS was 
admitted to the neurological department due to an intense 
and disabling migrainous headache that had started a few 
days earlier. The headache was characterized by a pressing, 
intense and persistent pain not responding to paracetamol, 
NSAIDs, triptans, or codeine. At the time of admission, she 
was on prednisolone 5 mg × 1 due to severe systemic dis-
ease activity. She fulfilled the AECG‐criteria for pSS2; had 
subjective dryness of the mouth and eyes, objective reduced 
tear and saliva production, a positive labial biopsy showing 
small salivary glands with focus score 2.2, and anti‐SSA and 
SSB antibodies in high concentrations. IgG in serum was 
considerably increased 40.5 g/L (5.4‐18.2), and ESR was 
114/mm/h, Hgb 11.1 g/dL (11.7‐15.3), all indicating high 
immunological activity. Extensive investigations by clinical 
immunologists did not reveal any other disease, especially 
not lymphoma.
The patient had not suffered from headaches earlier in 
her life and had no family history of migraine. However, 
during pregnancy two years prior to the pSS diagnosis, she 
had experienced visual and sensory aura phenomena with-
out headache. She underwent extensive clinical neurologi-
cal examinations without revealing any additional abnormal 
findings. Cerebral MRI with and without gadolinium and 
intracranial MRI angiography with both arterial and venous 
series were normal, as was opening pressure on lumbar punc-
ture. Leukocyte and protein content was normal, IgG slightly 
increased to 0.07 g/L (ref. 0.00‐0.04 g/L), and isoelectric 
focusing of cerebrospinal fluid (CSF) revealed 6‐7 oligo-
clonal bands, also present in serum. Borrelia IgG and IgM 
and Treponema pallidum haemagglutination test were nega-
tive. No atypical cells were found, and flow cytometry only 
showed a reactive pattern. A diagnosis of headache secondary 
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Key Clinical Message
A severe and persistent migrainous headache in a patient with primary Sjøgren's 
syndrome unresponsive to treatment with immunosuppressive drugs, triptans, opi-
oids, and NSAIDs, responded successfully to intrathecal B‐cell depletion with rituxi-
mab. We hypothesize that brain‐resident autoreactive B cells were involved in 
headache pathogenesis and were eliminated by this procedure.
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to inflammatory disease was made at the neurological depart-
ment. She first received weekly intravenous (i.v.) pulses of 
methylprednisolone 1000 mg and was started on azathioprine 
50 mg×2 with moderate response on headaches.
Because of persistent high disease activity, it was de-
cided to try B‐cell depletion with rituximab. She received 
two initial i.v. doses of 1000 mg 14 days apart, and thereaf-
ter 1000 mg every 6 months. In addition, she repeatedly re-
ceived 1000 mg methylprednisolone every second to fourth 
week with good but only short‐lasting effect on malaise and 
headaches (2‐3 days). Nevertheless, over time general dis-
ease activity and headache pain gradually declined on this 
regimen and serum IgG levels normalized. However, head-
aches tended to increase at the end of intervals between 
rituximab infusions. Azathioprine was stopped and meth-
otrexate added with some positive effect on the remaining 
headaches.
Almost four years after the initial headaches and still on 
rituximab, she suddenly started to have aura episodes with 
visual and sensory phenomena. Aura episodes went on for 
days with up to four episodes a day, each lasting for hours. 
Headaches were bi‐frontotemporal, pressing, intense, per-
sistent and accompanied by nausea and vomiting. On a visual 
analogue scale 0‐10, she rated the intensity as 10. The head-
aches again responded briefly to i.v. methylprednisolone that 
she received regularly up to twice a week. Rituximab was 
stopped and she consecutively was treated with mycopheno-
late‐mofetil, tocilizumab, and belimumab to dampen what 
was assumed to be high immunological activity as cause of 
the headache. Although she reached partial remission of her 
pSS on tocilizumab, headaches did not resolve and were per-
sistent with worsening episodes, pressing and sometimes pul-
sating, accompanied by hypersensitivity to light and sounds, 
nausea and sometimes vomiting. She avoided activity and 
preferred to be in bed. She continued to have frequent and 
multiple aura episodes.
Her headaches, now presenting as chronic migraine 
with aura, were classified according to the International 
Classification of Headache Disorders criteria, as headache 
secondary to an inflammatory disease, namely pSS.3 At this 
time point, the patient was in a paradoxical clinical remission 
concerning her systemic disease including normal routine 
hematological and routine laboratory tests and IgG levels, 
but with severe and disabling headaches. As she had never 
experienced migraine prior to pSS, a pSS‐associated cerebral 
process or disturbance not controlled by systemic rituximab 
was suspected.
It is well known that ectopic germinal centers consist-
ing of T‐, B‐, plasma cells, and follicular dendritic cells 
may develop in immunological diseases with high immu-
nological activity and take the structural shape of a lymph 
node.4 The presence of these germinal centers in pSS seems 
to distinguish a certain disease phenotype with high disease 
activity and increased tendency for malignant transforma-
tions to B‐cell lymphomas, and can be seen in 20%‐40% of 
pSS patients.5 Activated T‐ and B cells are able to cross an 
intact blood‐brain barrier, and we therefore hypothesized 
that the patient could have brain resident immune cells that 
were not evident on a recently performed MRI or in the 
cerebrospinal fluid. These B cells would not have been de-
pleted by rituximab as this drug is prevented from passing 
the blood‐brain barrier. This could affect/disturb the ce-
rebral homeostasis, thus trigging and maintaining the mi-
grainous headaches. Ectopic germinal centers in the brain 
have been described in diseases like multiple sclerosis but 
not in humans with pSS.6
To target potential B‐cell migraine generators, she re-
ceived an intrathecal (IT) injection of 10 mg rituximab in 
4 mL 0.9% NaCl after informed consent. Concomitantly, 
methylprednisolone 500 mg i.v., oral cetirizine 10 mg, and 
paracetamol 1000 mg were given as premedication. After 
few days, she responded with reduced frequency of aura 
episodes and intensity of headaches. After three weeks, 
headache and aura reappeared and a new IT injection was 
given with the same positive response. Encouraged by 
these results, we now gradually increased the dosage and 
the intervals between injections. Two and a half year after 
the initial dose she is on a stable regimen consisting of 
25 mg rituximab IT every 3 months. On this regimen, she 
experiences almost total relief of headaches and aura at-
tacks with an endurance of at least three months and is now 
able to participate in most daily activities. No side effects 
or complications to the procedure were observed except for 
transient postpunction headache. As systemic treatment she 
has continued to receive belimumab 640 mg i.v. and meth-
ylprednisolone 1000 mg i.v. monthly.
In conclusion, intrathecal rituximab injections may rep-
resent a treatment option for severe headache in patients 
with autoimmune diseases such as pSS and possibly SLE. 
The mechanism is unknown but possibly involves depletion 
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